Rabi Hanna, an expert at The Cleveland Clinic, Subarna Chakravorty from King’s College Hospital, and Ali Taher from the American University of Beirut dive into groundbreaking updates in sickle cell disease (SCD) and thalassemia. They discuss the promising results of the RUBY trial and the substantial findings from the ENERGIZE trial, highlighting improved hemoglobin levels. The conversation also tackles the high costs and complexities of gene therapies, unmet needs in patient care, and the critical need for better access and innovative treatments.
